Voltar
Errata Acesso aberto Revisado por pares
BIBTEX RIS

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

2020; Adis, Springer Healthcare; Volume: 7; Issue: 1 Linguagem: Inglês

10.1007/s40801-020-00184-w

ISSN

2199-1154

Autores

Néstor Szerman, Ignacio Basurte-Villamor, Pablo Vega, José Martı́nez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau‐López, Mario De Matteis, F. Árias,

Tópico(s)

Pharmaceutical studies and practices

Resumo

A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].

Referência(s)